- Home
- BTAI vs HIHO Comparison
BTAI vs HIHO Comparison
Compare BTAI & HIHO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- HIHO
- Stock Information
- Founded
- BTAI 2017
- HIHO 1990
- Country
- BTAI United States
- HIHO Hong Kong
- Employees
- BTAI N/A
- HIHO N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- HIHO Industrial Machinery/Components
- Sector
- BTAI Health Care
- HIHO Industrials
- Exchange
- BTAI Nasdaq
- HIHO Nasdaq
- Market Cap
- BTAI 8.3M
- HIHO 8.3M
- IPO Year
- BTAI 2018
- HIHO 1996
- Fundamental
- Price
- BTAI $1.93
- HIHO $1.63
- Analyst Decision
- BTAI Buy
- HIHO
- Analyst Count
- BTAI 5
- HIHO 0
- Target Price
- BTAI $34.60
- HIHO N/A
- AVG Volume (30 Days)
- BTAI 289.2K
- HIHO 11.2K
- Earning Date
- BTAI 08-05-2025
- HIHO 07-31-2025
- Dividend Yield
- BTAI N/A
- HIHO 7.36%
- EPS Growth
- BTAI N/A
- HIHO N/A
- EPS
- BTAI N/A
- HIHO 0.02
- Revenue
- BTAI $1,852,000.00
- HIHO $7,412,000.00
- Revenue This Year
- BTAI $5.03
- HIHO N/A
- Revenue Next Year
- BTAI $291.01
- HIHO N/A
- P/E Ratio
- BTAI N/A
- HIHO $82.00
- Revenue Growth
- BTAI 5.47
- HIHO 17.26
- 52 Week Low
- BTAI $1.17
- HIHO $1.40
- 52 Week High
- BTAI $21.92
- HIHO $2.88
- Technical
- Relative Strength Index (RSI)
- BTAI 56.97
- HIHO 27.65
- Support Level
- BTAI $1.69
- HIHO $1.69
- Resistance Level
- BTAI $2.08
- HIHO $1.75
- Average True Range (ATR)
- BTAI 0.20
- HIHO 0.04
- MACD
- BTAI 0.02
- HIHO -0.02
- Stochastic Oscillator
- BTAI 61.84
- HIHO 0.00
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About HIHO Highway Holdings Limited
Highway Holdings Ltd is a holding company. The company is a manufacturer of metal, plastic, electric and electronic components for original equipment manufacturers (OEM) and contract manufacturers. Its operating segment includes Metal stamping and mechanical OEM and Electric OEM. The metal stamping segment focuses on the manufacturing and sale of metal parts and components. The company generates maximum revenue from the Metal stamping and mechanical OEM segment. Geographically, it derives a majority of its revenue from Europe and also has a presence in Hong Kong and China, North America, and Other Asian countries.